Dana-Farber Cancer Institute
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Kidney cancer
FollowWhat is new in Kidney cancer research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- 177Lu-TLX250Phase 3 · NCT07197580 · NCT07870746
- 89Zr-TLX250 PET/CTPhase 3 · NCT06750419
- AbexinostatPhase 3 · NCT03592472
- AbirateronePhase 3 · NCT07620574
- Active ComparatorPhase 3 · NCT04510597
- AnlotinibPhase 3 · NCT07470840 · NCT07881900
- AtezolizumabPhase 3 · NCT07620574 · NCT03845166 · NCT05092373 · NCT05411081 · NCT04981509 · NCT05765084 · NCT03170960 · NCT06444815 · NCT05581004
- AtorvastatinPhase 3 · NCT07630363 · NCT05796973
- AvelumabPhase 3 · NCT03845166 · NCT03815643 · NCT05327686 · NCT05267626
- AxitinibPhase 3 · NCT03092856 · NCT06962787 · NCT06279403 · NCT07816770 · NCT07630363 · NCT05808608 · NCT07123090 · NCT04522323 · NCT06364631 · NCT05768464 · NCT03172754 · NCT05969496 · NCT05817903 · NCT06690697 · NCT07383441 · NCT07469683 · NCT07776717 · NCT05327686 · NCT03595124 · NCT07227415
- axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanibPhase 3 · NCT06726421
- Axitinib plus ToripalimabPhase 3 · NCT05738694 · NCT07744932
- BelzutifanPhase 3 · NCT05899049 · NCT07593040 · NCT07840001 · NCT03401788 · NCT03634540 · NCT05468697 · NCT04586231 · NCT07023432 · NCT07167329 · NCT04736706 · NCT06234605 · NCT07187778 · NCT07489495 · NCT07049926 · NCT02974738 · NCT05030506 · NCT05239728 · NCT07227402 · NCT04195750
- BenmelstobartPhase 3 · NCT07881900
- BiopsyPhase 3 · NCT04989959 · NCT05269381 · NCT06866262 · NCT06661720 · NCT02210117
- Biospecimen CollectionPhase 3 · NCT03866382 · NCT02496208 · NCT07689240 · NCT07037004 · NCT02298959 · NCT02465060 · NCT06390826 · NCT03155620 · NCT05411081 · NCT07128680 · NCT04981509 · NCT03793166 · NCT07516366 · NCT05269381 · NCT04514484 · NCT03210714 · NCT06866262 · NCT07578025 · NCT06447103 · NCT07383441 · NCT04851119 · NCT06432036 · NCT07510334 · NCT04071223 · NCT03213704 · NCT07226544 · NCT06661720 · NCT04616560 · NCT05327686 · NCT04322318 · NCT07716735 · NCT03213652 · NCT07576725 · NCT05830058
- Bone ScanPhase 3 · NCT03866382 · NCT07689240 · NCT03155620 · NCT05411081 · NCT07128680 · NCT04981509 · NCT03793166 · NCT03210714 · NCT07043608 · NCT07578025 · NCT06447103 · NCT07383441 · NCT04071223 · NCT03213704 · NCT05327686 · NCT04322318 · NCT03213652
- CabozantinibPhase 3 · NCT07293351 · NCT05663710 · NCT07620574 · NCT03541902 · NCT04413123 · NCT06026410 · NCT03634540 · NCT05263050 · NCT05048212 · NCT07848295 · NCT05241561 · NCT04586231 · NCT06835972 · NCT03793166 · NCT05135975 · NCT03170960 · NCT02293980 · NCT05127824 · NCT06364631 · NCT03937219 · NCT04022343 · NCT07077161 · NCT07383441 · NCT06132945 · NCT03635892 · NCT05012371 · NCT05361720 · NCT02867592 · NCT05327686 · NCT07011719 · NCT07227402 · NCT05536141 · NCT04322955 · NCT07187869
- Cabozantinib-matched placeboPhase 3 · NCT03937219
- CasdatifanPhase 3 · NCT07293351 · NCT07000149 · NCT07397611 · NCT07011719 · NCT05536141 · NCT07227415 · NCT07748988
- Clonidine HCLPhase 3 · NCT07092566
- Clostridium butyricum CBM 588 Probiotic StrainPhase 3 · NCT07383441 · NCT05122546
- Combination PD-1/PD-L1 ICI + VEGFR-TKIPhase 3 · NCT05219318
- Computed TomographyPhase 3 · NCT03866382 · NCT02713269 · NCT02496208 · NCT07689240 · NCT07037004 · NCT04147494 · NCT02298959 · NCT04320888 · NCT02465060 · NCT06390826 · NCT03155620 · NCT05411081 · NCT07128680 · NCT01575548 · NCT04981509 · NCT03793166 · NCT07516366 · NCT05269381 · NCT04514484 · NCT03210714 · NCT05641935 · NCT05863351 · NCT06866262 · NCT07578025 · NCT06447103 · NCT07383441 · NCT06432036 · NCT01038778 · NCT07510334 · NCT04071223 · NCT03213704 · NCT07226544 · NCT06661720 · NCT04616560 · NCT05327686 · NCT04322318 · NCT07716735 · NCT03213652 · NCT07576725 · NCT05830058 · NCT06500455
- Cytoreductive NephrectomyPhase 3 · NCT06279403 · NCT04510597 · NCT04322955
- DurvalumabPhase 3 · NCT03682289 · NCT03288532 · NCT05043090 · NCT03308396
- Echocardiography TestPhase 3 · NCT03866382 · NCT02496208 · NCT07689240 · NCT02465060 · NCT06390826 · NCT07226544 · NCT04616560
- EnzalutamidePhase 3 · NCT07620574
- EpinephrinePhase 3 · NCT07092566
- EtoposidePhase 3 · NCT03669783 · NCT05384821 · NCT04322318
- EverolimusPhase 3 · NCT02811861 · NCT05012371 · NCT01217931 · NCT04195750
- ExparelPhase 3 · NCT07092566
- Fractionated Stereotactic Radiation TherapyPhase 3 · NCT06500455
- IpilimumabPhase 3 · NCT07293351 · NCT03866382 · NCT04416568 · NCT02496208 · NCT04413123 · NCT03203473 · NCT07188896 · NCT07195682 · NCT05048212 · NCT07401875 · NCT07611825 · NCT07128680 · NCT03793166 · NCT06364631 · NCT06362369 · NCT06866262 · NCT06047379 · NCT03937219 · NCT07383441 · NCT03873402 · NCT02950766 · NCT04388852 · NCT07510334 · NCT05361720 · NCT05327686 · NCT05407441 · NCT05501054 · NCT05536141 · NCT02210117 · NCT06708949 · NCT07227415 · NCT05176483 · NCT05215470
- KetorolacPhase 3 · NCT05842044 · NCT07092566
- LenvatinibPhase 3 · NCT05899049 · NCT04977453 · NCT06962787 · NCT04586231 · NCT04522323 · NCT06364631 · NCT04736706 · NCT02811861 · NCT07383441 · NCT07715565 · NCT07571551 · NCT05012371 · NCT05030506 · NCT04393350 · NCT05327686
- lidocaine infusionPhase 3 · NCT06349668
- Lu-177 PSMA-617Phase 3 · NCT06959433
- Magnetic Resonance ImagingPhase 3 · NCT03866382 · NCT02496208 · NCT07689240 · NCT04320888 · NCT02465060 · NCT06390826 · NCT03155620 · NCT05411081 · NCT07128680 · NCT01575548 · NCT04981509 · NCT03793166 · NCT05269381 · NCT04514484 · NCT03210714 · NCT05641935 · NCT05863351 · NCT06866262 · NCT06447103 · NCT07383441 · NCT04071223 · NCT03213704 · NCT04616560 · NCT05327686 · NCT04258462 · NCT04322318 · NCT07716735 · NCT03213652 · NCT07576725 · NCT06500455
- MRIPhase 3 · NCT06661720
- NephrectomyPhase 3 · NCT07516366 · NCT05738694 · NCT03055013 · NCT00715442 · NCT07226544
- NivolumabPhase 3 · NCT06053658 · NCT03866382 · NCT04416568 · NCT05663710 · NCT07620574 · NCT02496208 · NCT04413123 · NCT07223424 · NCT03203473 · NCT07188896 · NCT05263050 · NCT02465060 · NCT05048212 · NCT07848295 · NCT07401875 · NCT06863311 · NCT07128680 · NCT03793166 · NCT04514484 · NCT02293980 · NCT06284564 · NCT06364631 · NCT03172754 · NCT06362369 · NCT05239533 · NCT04810078 · NCT05817903 · NCT06866262 · NCT06047379 · NCT03055013 · NCT03937219 · NCT07383441 · NCT03873402 · NCT06794229 · NCT06764771 · NCT06132945 · NCT03635892 · NCT07510334 · NCT05678673 · NCT05361720 · NCT05327686 · NCT05407441 · NCT06638931 · NCT03595124 · NCT05501054 · NCT04322955 · NCT05267626 · NCT03589339 · NCT02210117 · NCT07576725 · NCT06265285 · NCT05176483 · NCT05122546 · NCT05215470 · NCT07187869
- Nivolumab & IpilimumabPhase 3 · NCT07338981
- Nivolumab + IpilimumabPhase 3 · NCT07338981
- Nivolumab and Recombinant Human HyaluronidasePhase 3 · NCT07383441
- Nivolumab and rHuPH20Phase 3 · NCT04810078
- PazopanibPhase 3 · NCT03592472 · NCT07087158 · NCT01217931
- Pazopanib HydrochloridePhase 3 · NCT01575548 · NCT01684397
- PembrolizumabPhase 3 · NCT05899049 · NCT05544929 · NCT03474497 · NCT07840001 · NCT05824975 · NCT05128487 · NCT07689240 · NCT07037004 · NCT06962787 · NCT07223424 · NCT06146777 · NCT02298959 · NCT06307431 · NCT06270706 · NCT06099782 · NCT05653882 · NCT02432963 · NCT05269381 · NCT04787042 · NCT05155033 · NCT06364631 · NCT05969496 · NCT04736706 · NCT04485013 · NCT02811861 · NCT06047379 · NCT07187778 · NCT07383441 · NCT05614102 · NCT04140526 · NCT04483778 · NCT03647163 · NCT05581004 · NCT05030506 · NCT05239728 · NCT06004336 · NCT04393350 · NCT06661720 · NCT07634380 · NCT05327686 · NCT07749586 · NCT05856981 · NCT05329532 · NCT02721732 · NCT03589339
- Pembrolizumab/QuavonlimabPhase 3 · NCT05899049 · NCT04736706
- Perfusion CT scanPhase 3 · NCT01224288
- Positron Emission TomographyPhase 3 · NCT03866382 · NCT07689240 · NCT04147494 · NCT04320888 · NCT03155620 · NCT04981509 · NCT03210714 · NCT06447103 · NCT01038778 · NCT04071223 · NCT04322318 · NCT03213652 · NCT05830058
- PrednisonePhase 3 · NCT07620574 · NCT05176483
- Reduced dose intensity of IOPhase 3 · NCT05078047
- Ropivacaine HCLPhase 3 · NCT07092566
- SavolitinibPhase 3 · NCT03091192 · NCT05043090
- SBRT(Stereotatic Body Radiation Therapy)Phase 3 · NCT06467097
- Serplulimab + FruquintinibPhase 3 · NCT07904156
- spinal analgesia with morphine and bupivacainePhase 3 · NCT06349668
- Stereotactic Ablative RadiotherapyPhase 3 · NCT05863351 · NCT05327686
- Stereotactic body radiotherapy (SBRT)Phase 3 · NCT06726421
- Stereotactic RadiosurgeryPhase 3 · NCT02713269 · NCT06500455
- SunitinibPhase 3 · NCT03091192 · NCT06390826 · NCT02811861 · NCT00715442 · NCT07165418 · NCT05024214 · NCT05043090 · NCT07881900
- Sunitinib MalatePhase 3 · NCT03541902 · NCT02465060 · NCT05678673
- Systemic TherapyPhase 3 · NCT05863351 · NCT06613269
- TivozanibPhase 3 · NCT06053658 · NCT06661720
- treatment Actinomycin-DPhase 3 · NCT03669783
- treatment CarboplatinPhase 3 · NCT03669783
- treatment DoxorubicinPhase 3 · NCT03669783
- treatment VincristinPhase 3 · NCT03669783
- TremelimumabPhase 3 · NCT03288532
- Vorolanib Tablets+EverolimusPhase 3 · NCT07165418
- XL092Phase 3 · NCT03845166 · NCT06863311 · NCT05678673
- ZanzalintinibPhase 3 · NCT07620574 · NCT07043608 · NCT07578025 · NCT06794229 · NCT07489495 · NCT07049926 · NCT07227402 · NCT05176483
- AlectinibPhase 2/3 · NCT05770037
- Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapyPhase 2/3 · NCT03755739
- [18F]F-RESCA-R8B4Phase 2 · NCT06852638
- [18F]F-RESCA-RCCB6Phase 2 · NCT06852638
- [18F]F-RESCA-RD06Phase 2 · NCT06852638
- [18F]RCCB6Phase 2 · NCT06680089
- [68Ga]Ga-NOTA-R8B4Phase 2 · NCT06852638
- [68Ga]Ga-NOTA-RD06Phase 2 · NCT06852638
- 177Lu-labeled-girentuximabPhase 2 · NCT05239533
- 177Lu-PSMA-617Phase 2 · NCT06783348 · NCT06964958
- 18F-FDG PET/CTPhase 2 · NCT06613269
- 5-Aminolevulinic acid Hydrochloride (Gliolan®)Phase 2 · NCT06948552 · NCT07828704
- 68Ga-NY104 PET/CTPhase 2 · NCT06613269
- 82-Rb injectionPhase 2 · NCT07346404
- 89Zr-DFO-AtezolizumabPhase 2 · NCT04006522
- 89Zr-GirentuximabPhase 2 · NCT07077083
- 9-ING-41Phase 2 · NCT03678883
- AcetaminophenPhase 2 · NCT05842044
- AdavosertibPhase 2 · NCT02465060 · NCT03284385
- Adjuvant PembrolizumabPhase 2 · NCT05319015
- AfatinibPhase 2 · NCT02465060
- Afatinib DimaleatePhase 2 · NCT02465060
- AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orallyPhase 2 · NCT06035224
- AL8326 40 mgPhase 2 · NCT05363280
- AL8326 60 mgPhase 2 · NCT05363280
- AL8326 80 mg--stoppedPhase 2 · NCT05363280
- AldesleukinPhase 2 · NCT05155033 · NCT01038778 · NCT02830724 · NCT05267626
- Anlotinib hydrochloride + Benmelstobart + Partial nephrectomyPhase 2 · NCT07627464
- Anlotinib plus SintilimabPhase 2 · NCT05220267
- Anlotinib, Everolimus and TislelizumabPhase 2 · NCT06211790
- Anti-OX40 Antibody PF-04518600Phase 2 · NCT03092856
- Anti-PD-1 monoclonal antibodyPhase 2 · NCT06255223
- APL-101 Oral CapsulesPhase 2 · NCT03175224
- Autologous alpha-DC1/TBVA vaccinePhase 2 · NCT05127824
- Axitinib (VEGF-TKI)Phase 2 · NCT06889649
- Axitinib Oral Tablet [Inlyta]Phase 2 · NCT03438708
- BalstilimabPhase 2 · NCT07516366
- BemarituzumabPhase 2 · NCT07470840
- bevacizumabPhase 2 · NCT05824975 · NCT04981509 · NCT06047379 · NCT01217931 · NCT06839105 · NCT01684397 · NCT02210117 · NCT05029882
- BinimetinibPhase 2 · NCT02465060
- Biopsy ProcedurePhase 2 · NCT02496208 · NCT02298959 · NCT02465060 · NCT06390826 · NCT03155620 · NCT04981509 · NCT07510334 · NCT07226544 · NCT04322318 · NCT07716735
- BL-B01D1Phase 2 · NCT06962787 · NCT05393427
- Blood samplePhase 2 · NCT05241561
- BMS-986213 (Relatlimab-Nivolumab FDC)Phase 2 · NCT06708949
- Bone Marrow Aspiration and BiopsyPhase 2 · NCT03155620 · NCT03210714 · NCT03213704 · NCT03213652
- BotensilimabPhase 2 · NCT07516366
- C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03Phase 2 · NCT07578025
- Cabozantinib 80 MGPhase 2 · NCT05931393
- Cabozantinib S-malatePhase 2 · NCT03866382 · NCT02496208 · NCT05092373 · NCT05411081 · NCT04514484 · NCT04071223 · NCT02867592 · NCT05122546
- Cadonilimab,LenvatinibPhase 2 · NCT07909265
- Cancer Therapeutic ProcedurePhase 2 · NCT07285044
- CapivasertibPhase 2 · NCT02465060
- CarboplatinPhase 2 · NCT06047379 · NCT04322318
- Carboplatin.Phase 2 · NCT03678883
- cardonilimabPhase 2 · NCT06670300
- cardonilizumab combined with renvastinibPhase 2 · NCT06574412
- CediranibPhase 2 · NCT03741426
- CemiplimabPhase 2 · NCT03972657 · NCT07188896 · NCT06699602 · NCT06413680
- Cemiplimab 350 MG Intravenous SolutionPhase 2 · NCT07223541
- CeralasertibPhase 2 · NCT03682289
- Clinical EncounterPhase 2 · NCT05969860
- Clostridium butyricum CBM588 StrainPhase 2 · NCT07037004
- Complete Surgical ResectionPhase 2 · NCT04968990
- Computed Tomography with ContrastPhase 2 · NCT04981509
- Computerized tomography (CT) ScanPhase 2 · NCT07043608
- contrast agent perflutren lipidPhase 2 · NCT07225114
- Contrast-Enhanced UltrasoundPhase 2 · NCT05641935
- CopanlisibPhase 2 · NCT02465060
- Copanlisib HydrochloridePhase 2 · NCT02465060
- CrizotinibPhase 2 · NCT02465060
- CyclophosphamidePhase 2 · NCT05672459 · NCT04897321 · NCT05269381 · NCT07564232 · NCT04696731 · NCT07297667 · NCT02830724 · NCT04322318
- DabrafenibPhase 2 · NCT02465060
- Dabrafenib MesylatePhase 2 · NCT02465060
- DasatinibPhase 2 · NCT02465060
- DD-4A Chemotherapy RegimenPhase 2 · NCT04968990
- DefactinibPhase 2 · NCT02465060
- Defactinib HydrochloridePhase 2 · NCT02465060
- Deferred Cytoreductive NephrectomyPhase 2 · NCT07816770 · NCT07776717
- doxorubicinPhase 2 · NCT05824975 · NCT04322318
- Doxorubicin.Phase 2 · NCT03678883
- Drugs NivolumabPhase 2 · NCT06708949
- EnsartinibPhase 2 · NCT03155620 · NCT03213652
- EntinostatPhase 2 · NCT03501381 · NCT01038778
- EntrectinibPhase 2 · NCT02650401 · NCT02568267
- Envafolimab Injection, Axitinib TabletsPhase 2 · NCT07159191
- Envafolimab+LenvatinibPhase 2 · NCT07256223
- ErdafitinibPhase 2 · NCT02465060 · NCT03155620 · NCT03210714
- ErlotinibPhase 2 · NCT04981509
- EvolocumabPhase 2 · NCT06284564
- Fecal Microbiota Transplant (FMT)Phase 2 · NCT05286294
- FexagratinibPhase 2 · NCT02465060
- FianlimabPhase 2 · NCT07188896 · NCT06699602
- Fianlimab 1600 MG Intravenous SolutionPhase 2 · NCT07223541
- Fruquintinib combined with SerplulimabPhase 2 · NCT05831891
- Gemcitabine - 21 day cyclePhase 2 · NCT03678883
- Gemcitabine - 28 day cyclePhase 2 · NCT03678883
- High Dose IL-2Phase 2 · NCT02306954
- High-dose Radiotherapy (HDRT)Phase 2 · NCT06255223
- HydromorphonePhase 2 · NCT05842044
- Hyperpolarized 13C,15N2-ureaPhase 2 · NCT04258462
- Hyperpolarized Carbon C 13 PyruvatePhase 2 · NCT04258462
- IBI363Phase 2 · NCT06281678
- IBR854Phase 2 · NCT07087158
- IbuprofenPhase 2 · NCT05842044
- IfosfamidePhase 2 · NCT04322318
- IMSA101Phase 2 · NCT06601296
- Interleukin-2Phase 2 · NCT03501381
- Intermittent PD-1/PD-L1 ICI + VEGFR-TKIPhase 2 · NCT07175480
- Intismeran autogenePhase 2 · NCT06307431
- Investigator Choice of Bone Strengthening Agents (BSA)Phase 2 · NCT07043608
- Iparomlimab and Tuvonralimab in combination with LenvatinibPhase 2 · NCT07741617
- Iparomlimab and Tuvonralimab Injection in combination with Lenvatinib or AxitinibPhase 2 · NCT07277972
- IpatasertibPhase 2 · NCT02465060
- Ipilimumab InjectionPhase 2 · NCT07715565
- Ipilimumab, Nivolumab, Pembrolizumab or AtezolizumabPhase 2 · NCT03693014
- IrinotecanPhase 2 · NCT05384821 · NCT03678883 · NCT04322318
- IvocizumabPhase 2 · NCT06683846
- IvonescimabPhase 2 · NCT07877194 · NCT06940518 · NCT07226544
- Ivonescimab (dose level 1) combined with CadonilimabPhase 2 · NCT07877194
- Ivonescimab (dose level 2) combined with CadonilimabPhase 2 · NCT07877194
- Ivonescimab combined with IpilimumabPhase 2 · NCT07877194
- IvosidenibPhase 2 · NCT03155620 · NCT04195555
- JS004Phase 2 · NCT06690697
- JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)Phase 2 · NCT06730932
- LarotrectinibPhase 2 · NCT02465060
- Larotrectinib SulfatePhase 2 · NCT02465060 · NCT03155620 · NCT03213704
- LenvatinbPhase 2 · NCT07593040
- Lenvatinib 20mg QDPhase 2 · NCT07460206
- Lenvatinib MesylatePhase 2 · NCT04393350
- LomustinePhase 2 · NCT03678883
- Low-dose Radiotherapy (LDRT)Phase 2 · NCT06255223
- Multigated Acquisition ScanPhase 2 · NCT02465060 · NCT04616560
- Mutation Carrier ScreeningPhase 2 · NCT03155620
- N-803 + AtezolizumabPhase 2 · NCT03228667
- N-803 + Atezolizumab + PD-L1 t-haNKPhase 2 · NCT03228667
- N-803 + AvelumabPhase 2 · NCT03228667
- N-803 + Avelumab + PD-L1 t-haNKPhase 2 · NCT03228667
- N-803 + Docetaxel + NivolumabPhase 2 · NCT03228667
- N-803 + Docetaxel + PembrolizumabPhase 2 · NCT03228667
- N-803 + DurvalumabPhase 2 · NCT03228667
- N-803 + Durvalumab + PD-L1 t-haNKPhase 2 · NCT03228667
- N-803 + NivolumabPhase 2 · NCT03228667
- N-803 + Nivolumab + PD-L1 t-haNKPhase 2 · NCT03228667
- N-803 + PembrolizumabPhase 2 · NCT03228667
- N-803 + Pembrolizumab + PD-L1 t-haNKPhase 2 · NCT03228667
- Nab paclitaxel.Phase 2 · NCT03678883
- Neoadjuvant ipilimumabPhase 2 · NCT05148546
- Neoadjuvant LenvatinibPhase 2 · NCT05319015
- Neoadjuvant nivolumabPhase 2 · NCT05148546
- Neoadjuvant PembrolizumabPhase 2 · NCT07593040 · NCT05319015
- Neoadjuvant relatlimabPhase 2 · NCT05148546
- Nivolumab (240 mg)Phase 2 · NCT07494435
- Nivolumab combined with IpilimumabPhase 2 · NCT07877194
- Non-Investigational Radiation Therapy (RT)Phase 2 · NCT07043608
- OlaparibPhase 2 · NCT03682289 · NCT03741426 · NCT03155620 · NCT03786796
- OsimertinibPhase 2 · NCT02465060
- OxycodonePhase 2 · NCT05842044
- Paclitaxel.Phase 2 · NCT03678883
- PalbociclibPhase 2 · NCT02465060 · NCT05468697 · NCT03155620 · NCT07123090
- Partial NephrectomyPhase 2 · NCT04968990 · NCT07627464
- Patient MonitoringPhase 2 · NCT06265285
- PD-1/PD-L1 ICI + VEGFR-TKIPhase 2 · NCT07615348
- Pembrolizumab (+) Berahyaluronidase alfaPhase 2 · NCT06099782
- Pembrolizumab + Enfortumab VedotinPhase 2 · NCT06302569
- Pembrolizumab 200 mg Q3WPhase 2 · NCT07460206
- Pembrolizumab injection plus metastasis directed treatment (surgery or RT)Phase 2 · NCT05578664
- PertuzumabPhase 2 · NCT02465060
- PI3K-beta Inhibitor GSK2636771Phase 2 · NCT02465060
- Positron Emission Tomography/Computed TomographyPhase 2 · NCT04006522 · NCT04989959
- Proton Beam Radiation (PBRT)Phase 2 · NCT04968990
- Proton Stereotactic Body Radiation therapy (SBRT)Phase 2 · NCT06376669
- Psilocybin therapyPhase 2 · NCT07072728
- Pucotenlimab combination with VorolanibPhase 2 · NCT07386158
- QL1706 Combined With LenvatinibPhase 2 · NCT07389629
- Radiation therapyPhase 2 · NCT05704985 · NCT06613269 · NCT06004336 · NCT04322318
- Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissectionPhase 2 · NCT05319015
- Radiologic ExaminationPhase 2 · NCT02465060
- Radionuclide ImagingPhase 2 · NCT04320888 · NCT02465060 · NCT06390826 · NCT03155620 · NCT03210714 · NCT03213704 · NCT03213652
- Radium Ra 223 DichloridePhase 2 · NCT04071223
- Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide SymporterPhase 2 · NCT07510334
- RelatlimabPhase 2 · NCT02465060
- RiluzolePhase 2 · NCT06580002
- RilvegostomigPhase 2 · NCT03741426 · NCT07115043
- SABRPhase 2 · NCT07744932 · NCT03589339
- Sacituzumab Tirumotecan (SKB264)Phase 2 · NCT07716917
- SamotolisibPhase 2 · NCT03155620
- SapanisertibPhase 2 · NCT02465060
- SasanlimabPhase 2 · NCT05665361 · NCT07123090
- SBRTPhase 2 · NCT02306954
- SelinexorPhase 2 · NCT05985161
- SelpercatinibPhase 2 · NCT04320888 · NCT03155620
- Selumetinib SulfatePhase 2 · NCT03155620
- Serplulimab in combination with FruquintinibPhase 2 · NCT07488533
- Sintilimab injectionPhase 2 · NCT07715565
- SLC-3010 + AxitinibPhase 2 · NCT07469683
- Sodium Fluoride F-18Phase 2 · NCT04981509
- SorafenibPhase 2 · NCT06690697
- SpartalizumabPhase 2 · NCT04802876
- Stereotactic Ablative Body Radiotherapy (SABR)Phase 2 · NCT06889649
- Stereotactic Ablative Radiation TherapyPhase 2 · NCT02141919 · NCT02473536
- Stereotactic Body Radiation TherapyPhase 2 · NCT04974671 · NCT05830058
- Stereotactic body radiation therapy (SBRT)Phase 2 · NCT04235777 · NCT07470840
- Stereotactic Body RadiotherapyPhase 2 · NCT03693014
- Steretactic radiotherapyPhase 2 · NCT04299646
- Sulfur Hexafluoride Lipid MicrospheresPhase 2 · NCT05641935
- Surgical ProcedurePhase 2 · NCT04322318
- Surgical ResectionPhase 2 · NCT04968990
- TaselisibPhase 2 · NCT02465060
- TazemetostatPhase 2 · NCT03155620 · NCT05407441
- Thermal Ablation TherapyPhase 2 · NCT02713269
- TipifarnibPhase 2 · NCT04284774 · NCT03155620
- TislelizumabPhase 2 · NCT04802876 · NCT05238883 · NCT05661955 · NCT05789069
- TopotecanPhase 2 · NCT04322318
- ToripalimabPhase 2 · NCT06584435 · NCT06279403 · NCT07611825 · NCT07816770 · NCT07630363 · NCT05768464 · NCT06690697 · NCT07776717 · NCT07571551
- Toripalimab and axitinibPhase 2 · NCT07172386
- TORIPALIMAB INJECTION(JS001 )Phase 2 · NCT06889649
- TQB2450 + AnlotinibPhase 2 · NCT07602101
- TrametinibPhase 2 · NCT02465060
- Transabdominal UltrasoundPhase 2 · NCT04322318
- TrastuzumabPhase 2 · NCT02465060
- Trastuzumab DeruxtecanPhase 2 · NCT04616560
- Trastuzumab EmtansinePhase 2 · NCT02465060
- UDCA (Ursodeoxycholic acid)Phase 2 · NCT07672860
- UlixertinibPhase 2 · NCT03698994 · NCT02465060 · NCT03155620
- Ultrasound ImagingPhase 2 · NCT07225114
- VemurafenibPhase 2 · NCT03155620
- VincristinePhase 2 · NCT05384821 · NCT04322318
- VismodegibPhase 2 · NCT02465060
- VolrustomigPhase 2 · NCT03741426 · NCT07000149
- Vorolanib + ToripalimabPhase 2 · NCT07047001
- Vorolanib combined with Everolimus FormationPhase 2 · NCT06730672
- Vorolanib TabletsPhase 2 · NCT07047001
- WGI-0301Phase 2 · NCT07494435
- X-Ray ImagingPhase 2 · NCT04320888 · NCT03155620 · NCT03210714 · NCT04851119 · NCT03213704 · NCT04322318 · NCT03213652
- Y-90 Selective Internal Radiation Therapy (SIRT)Phase 2 · NCT06642220
- YivoximabPhase 2 · NCT07488572
- Zanzalintinib and PembrolizumabPhase 2 · NCT07691476
- ZimberelimabPhase 2 · NCT05891171 · NCT07397611 · NCT05536141
- Zirconium Zr 89 GirentuximabPhase 2 · NCT06447103
- [177Lu]Lu-DPI-4452Phase 1/2 · NCT05706129
- [68Ga]Ga-DPI-4452Phase 1/2 · NCT05706129
- 177Lu girentuximabPhase 1/2 · NCT05663710
- 23ME-00610Phase 1/2 · NCT05199272
- A2B395Phase 1/2 · NCT06682793
- AB-2100Phase 1/2 · NCT06245915
- AbemaciclibPhase 1/2 · NCT06835972
- Aerosolized AldesleukinPhase 1/2 · NCT01590069
- AK104Phase 1/2 · NCT05808608
- AK112 monotherapyPhase 1/2 · NCT06472895
- AlintegimodPhase 1/2 · NCT06362369
- AngiogramPhase 1/2 · NCT06432036
- Anti-hCD70 CAR transduced PBLPhase 1/2 · NCT02830724
- ArabinoFuranosylGuanine [18F]F-AraGPhase 1/2 · NCT05663710
- ARV-6723Phase 1/2 · NCT07749586
- AU-007Phase 1/2 · NCT05267626
- Autologous or Allogeneic tumor cellsPhase 1/2 · NCT00722228
- AZD6750Phase 1/2 · NCT07115043
- BGB-A445Phase 1/2 · NCT05661955
- Bicalutamide in combination with SunitinibPhase 1/2 · NCT06222593
- BMS-936558-01Phase 1/2 · NCT04895709
- BMS-986340Phase 1/2 · NCT04895709
- BNT317 DL1Phase 1/2 · NCT06750185
- BNT317 DL2Phase 1/2 · NCT06750185
- BNT317 DL3Phase 1/2 · NCT06750185
- BNT317 DL4Phase 1/2 · NCT06750185
- BNT317 DL5Phase 1/2 · NCT06750185
- BNT317 DL6Phase 1/2 · NCT06750185
- BNT317 selected DLAPhase 1/2 · NCT06750185
- BNT317 selected DLBPhase 1/2 · NCT06750185
- cadonilimabPhase 1/2 · NCT06577961
- Carboplatin AUC-5Phase 1/2 · NCT04198766
- Carboplatin AUC-6Phase 1/2 · NCT04198766
- CiforadenantPhase 1/2 · NCT05501054
- Cis-Retinoic acidPhase 1/2 · NCT05384821
- Cisplatin 75mg/m2Phase 1/2 · NCT04198766
- Copper-64 labeled Granzyme B (64Cu-GRIP B)Phase 1/2 · NCT05888532
- Dendritic cell vaccinationPhase 1/2 · NCT05765084
- DocetaxelPhase 1/2 · NCT04140526 · NCT04895709 · NCT05176483
- Dual X-ray AbsorptiometryPhase 1/2 · NCT04851119
- EB-701/CA9-NKPhase 1/2 · NCT07551349
- EBNK-001 + IL-15 + PembrolizumabPhase 1/2 · NCT07410676
- eribulinPhase 1/2 · NCT05824975
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor KidneyPhase 1/2 · NCT07053462
- FludarabinePhase 1/2 · NCT04897321 · NCT07770802 · NCT07551349 · NCT07072234 · NCT07564232 · NCT04696731 · NCT07297667 · NCT02830724
- Fludarabine phosphatePhase 1/2 · NCT05672459
- Fludeoxyglucose F-18Phase 1/2 · NCT01038778
- FOLFIRI ProtocolPhase 1/2 · NCT06047379
- Gemcitabine (1000 mg/m2)Phase 1/2 · NCT04198766
- GI-101Phase 1/2 · NCT04977453
- GI-101APhase 1/2 · NCT04977453
- GI-102Phase 1/2 · NCT05824975
- GI-102 subcutaneous (SC)Phase 1/2 · NCT05824975
- GI-108Phase 1/2 · NCT07172802
- GM103 (Part A)Phase 1/2 · NCT06265025
- GM103 (Part B)Phase 1/2 · NCT06265025
- GM103 and Pembrolizumab (Part C)Phase 1/2 · NCT06265025
- GuadecitabinePhase 1/2 · NCT03308396
- HS-10516 + LenvatinibPhase 1/2 · NCT07097935
- HTL0039732 CapsulesPhase 1/2 · NCT05944237
- HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusionPhase 1/2 · NCT05944237
- humanized monoclonal anti-FGFR1 antibody OM-RCA-01Phase 1/2 · NCT07292168
- IL-2Phase 1/2 · NCT03474497
- INBRX-106 - Hexavalent OX40 agonist antibodyPhase 1/2 · NCT04198766
- Infusion of iNKT cells and CD8+T cellsPhase 1/2 · NCT03093688
- ipilimumab + nivolumabPhase 1/2 · NCT03647163
- Kidney Transplantation with Standard CarePhase 1/2 · NCT07053462
- Lenvatinib + EnvafolimabPhase 1/2 · NCT05024214
- leukapheresisPhase 1/2 · NCT05672459
- MDNA11Phase 1/2 · NCT05086692
- MDX2001Phase 1/2 · NCT06239194
- MicronJet600™ microneedle device (NanoPass)Phase 1/2 · NCT05329532
- Miltenyi CliniMACS Prodigy ® systemPhase 1/2 · NCT06625190
- Modi-1 ModitopePhase 1/2 · NCT05329532
- Nab paclitaxel 100mg/m2Phase 1/2 · NCT04198766
- NDI-101150Phase 1/2 · NCT05128487
- NEO212 Oral CapsulePhase 1/2 · NCT06047379
- Neoantigen Peptide VaccinePhase 1/2 · NCT05269381
- Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]Phase 1/2 · NCT04787042
- ONC-392Phase 1/2 · NCT04140526
- OnivydePhase 1/2 · NCT04901702
- OrellaninePhase 1/2 · NCT05287945
- paclitaxelPhase 1/2 · NCT05824975 · NCT06047379
- Paclitaxel 200mg/m2Phase 1/2 · NCT04198766
- PalbocicilibPhase 1/2 · NCT05665361
- Pembrolizumab (KEYTRUDA®)Phase 1/2 · NCT04977453 · NCT05086692
- pembrolizumab 200 mgPhase 1/2 · NCT04198766
- pembrolizumab 400 mgPhase 1/2 · NCT04198766
- Pemetrexed 500 mg/m2Phase 1/2 · NCT04198766
- PF-08634404Phase 1/2 · NCT07227415
- Phase Ib ARRY-614 + nivolumabPhase 1/2 · NCT04074967
- Phase Ib ARRY-614 + nivolumab+ipilimumabPhase 1/2 · NCT04074967
- Phase II ARRY-614 + nivolumabPhase 1/2 · NCT04074967
- Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)Phase 1/2 · NCT04074967
- Phase II ARRY-614 + nivolumab+ipilimumab (RCC)Phase 1/2 · NCT04074967
- Platinum/pemetrexed based chemotherapyPhase 1/2 · NCT05765084
- Positron Emission Tomography (PET)Phase 1/2 · NCT05888532
- PumitamigPhase 1/2 · NCT07293351 · NCT07195682 · NCT04895709
- RadioembolizationPhase 1/2 · NCT06432036
- RadiotherapyPhase 1/2 · NCT03474497
- REGN10597Phase 1/2 · NCT06413680
- REGN13089-M404-M2980Phase 1/2 · NCT07863024
- REGN15505Phase 1/2 · NCT07594106
- REGN15505+CemiplimabPhase 1/2 · NCT07594106
- REGN15505+REGN4336Phase 1/2 · NCT07594106
- REGN5678Phase 1/2 · NCT03972657
- RegorafenibPhase 1/2 · NCT06047379
- RetifanlimabPhase 1/2 · NCT07219576
- RuxolitinibPhase 1/2 · NCT07566897 · NCT07219576
- SargramostimPhase 1/2 · NCT05269381
- SHR-8068 ; SHR-4610Phase 1/2 · NCT07239596
- SHR-8068；Adebrelimab ；BevacizumabPhase 1/2 · NCT07239596
- Single Injection of IVS-3001- Anti - HLA-G CAR-T cellsPhase 1/2 · NCT05672459
- Single Photon Emission Computed TomographyPhase 1/2 · NCT06432036
- SL-28Phase 1/2 · NCT07341737
- SOCPhase 1/2 · NCT07749586
- SoC chemotherapy 1Phase 1/2 · NCT06750185
- SoC chemotherapy 2Phase 1/2 · NCT06750185
- ST-067Phase 1/2 · NCT04787042
- ST-1898 tabletsPhase 1/2 · NCT06127238
- TalazoparibPhase 1/2 · NCT04901702
- TegavivintPhase 1/2 · NCT04851119
- TemozolomidePhase 1/2 · NCT05384821 · NCT04901702
- trastuzumab deruxtecan (T-DXd)Phase 1/2 · NCT05824975
- TT-10Phase 1/2 · NCT04969315
- TT-4Phase 1/2 · NCT04969315
- UCB4594Phase 1/2 · NCT06380816
- VMD-102Phase 1/2 · NCT07636785
- VorolanibPhase 1/2 · NCT06577961
- VSV-IFNβ-NISPhase 1/2 · NCT03647163
- Yttrium Y 90 Glass MicrospheresPhase 1/2 · NCT06432036
- Zoledronic acidPhase 1/2 · NCT06625190
- [111In]-FPI-2107Phase 1 · NCT06147037
- [18F]PT2385Phase 1 · NCT04989959
- [203Pb]VMT-alpha-NETPhase 1 · NCT06479811
- [212Pb]VMT-alpha-NETPhase 1 · NCT06479811
- [225Ac]-FPI-2068Phase 1 · NCT06147037
- 111In-XYIMSR-01Phase 1 · NCT07062549
- 161Tb-PSMA-1 (radiopharmaceutical)Phase 1 · NCT07828249
- 177Lu-TLX250 and PeposertibPhase 1 · NCT05868174
- 18F-TRXPhase 1 · NCT06942104
- 21.15.GPC3-CAR T cellsPhase 1 · NCT06198296
- 68Ga-DOTATATEPhase 1 · NCT06479811
- 68Ga-NYM096 injectionPhase 1 · NCT07768306
- AB598Phase 1 · NCT05891171
- ABBV-400Phase 1 · NCT05029882
- ABBV-CLS-484Phase 1 · NCT04777994
- ACC-1898Phase 1 · NCT07252661
- AdagrasibPhase 1 · NCT06026410 · NCT06764771
- ADU-1805Phase 1 · NCT05856981
- AGAR T cellsPhase 1 · NCT04377932
- Akt Inhibitor MK2206Phase 1 · NCT01480154
- ALLO-316Phase 1 · NCT04696731
- ALLO-647Phase 1 · NCT04696731
- Anti-Human CD70 T-Cell InjectionPhase 1 · NCT07647744
- AUR107Phase 1 · NCT05865002
- AWT020Phase 1 · NCT06839105
- B7-H3 CAR T cellsPhase 1 · NCT04897321
- BAY2965501Phase 1 · NCT05614102
- Becotatug VedotinPhase 1 · NCT07584499
- BelrestotugPhase 1 · NCT05277051
- BezlutifanPhase 1 · NCT02293980
- Blood Specimen CollectionPhase 1 · NCT06942104
- BMS-986488Phase 1 · NCT06764771
- BMS-986506Phase 1 · NCT07195682
- BMS-986527Phase 1 · NCT07848295
- BrodalumabPhase 1 · NCT06673329
- CA9hu-1Phase 1 · NCT05698238
- CapecitabinePhase 1 · NCT06839105
- CARE T cellsPhase 1 · NCT04715191
- CATCH T cellsPhase 1 · NCT05103631
- CD70 CAR-T cellsPhase 1 · NCT05518253
- cell infusionPhase 1 · NCT03354390
- cetuximabPhase 1 · NCT04485013 · NCT06764771
- CGC738Phase 1 · NCT06870279
- ChemotherapyPhase 1 · NCT05704985
- CHT101Phase 1 · NCT06383507
- Cisplatin or CarboplatinPhase 1 · NCT06839105
- CK-301 (cosibelimab)Phase 1 · NCT03212404
- CLR 131Phase 1 · NCT03478462
- CT scanPhase 1 · NCT06673329
- CTX-10726Phase 1 · NCT07419841
- CUSP06Phase 1 · NCT06234423
- CyclophosphamatePhase 1 · NCT07072234
- CyclophosphamidPhase 1 · NCT07770802
- DarlifarnibPhase 1 · NCT06026410
- DCC-2812Phase 1 · NCT06966024
- DDI Probe CocktailPhase 1 · NCT05176483
- DEG6498Phase 1 · NCT07244835
- DexamethasonePhase 1 · NCT07072234
- DK210 (EGFR)Phase 1 · NCT05704985
- DostarlimabPhase 1 · NCT05277051
- DS-6000aPhase 1 · NCT04707248
- EnzelkitugPhase 1 · NCT05581004
- Epidural analgesiaPhase 1 · NCT06595329
- etakafusp alfa (AB248)Phase 1 · NCT05653882
- Exemestane 25 MGPhase 1 · NCT07369505
- EXS74539Phase 1 · NCT07517198
- Fecal Microbiota TransplantationPhase 1 · NCT04163289
- FluorouracilPhase 1 · NCT05891171
- FOLFIRIPhase 1 · NCT04485013
- FPI-2053Phase 1 · NCT06147037
- GCAR1Phase 1 · NCT07297667
- GSK5764227Phase 1 · NCT05277051
- HC-7366Phase 1 · NCT07401875 · NCT06234605
- HFB200301Phase 1 · NCT05238883
- HFB200603Phase 1 · NCT05789069
- HH160Phase 1 · NCT07623369
- HLX17Phase 1 · NCT07160335
- HS-IT101 monotherapyPhase 1 · NCT07770802
- HydroxychloroquinePhase 1 · NCT01480154
- IB-T101 injectionPhase 1 · NCT06819293
- IDOV-Immune (oncolytic vaccinia virus)Phase 1 · NCT06910657
- Immune checkpoint blockersPhase 1 · NCT05704985
- Implantable Microdevice (IMD)Phase 1 · NCT05700461
- INCA036873Phase 1 · NCT07195916
- Interleukin 2 subcutaneous injectionPhase 1 · NCT07770802
- Intrathecal opioid analgesiaPhase 1 · NCT06595329
- JANX008Phase 1 · NCT05783622
- JMKX003948Phase 1 · NCT06321250
- KFA115Phase 1 · NCT05544929
- L19IL2Phase 1 · NCT07566897
- LeucovorinPhase 1 · NCT05891171
- LNK001Phase 1 · NCT07564232
- Low Dose Rate Brachytherapy (LDR)Phase 1 · NCT04620603
- LXP1788 is administered intravenously via Port-APhase 1 · NCT06883539
- Lymphodepleting chemotherapyPhase 1 · NCT07072234
- M7824Phase 1 · NCT04235777
- Magnetic Resonance ElastographyPhase 1 · NCT02298959
- MEDI5752Phase 1 · NCT04522323
- MercaptopurinePhase 1 · NCT07716735
- MESNAPhase 1 · NCT04897321
- MGC026 Dose EscalationPhase 1 · NCT06242470
- MGC026 Dose for ExpansionPhase 1 · NCT06242470
- MK-3795Phase 1 · NCT02293980
- Modified Vaccinia Virus Ankara Vaccine Expressing p53Phase 1 · NCT02432963
- Nab-paclitaxelPhase 1 · NCT05092373
- Naptumomab estafenatox and durvalumabPhase 1 · NCT03983954
- NBTXR3Phase 1 · NCT03589339
- NelistotugPhase 1 · NCT05277051
- NEO-811Phase 1 · NCT07300241
- NeoVaxPhase 1 · NCT02950766
- Nivolumab + RelatlimabPhase 1 · NCT05176483
- NN3201Phase 1 · NCT06805825
- NXP900Phase 1 · NCT05873686
- OATD-02Phase 1 · NCT05759923
- Obinutuzumab, naptumomab estafenatox and durvalumabPhase 1 · NCT03983954
- Oral HS-10516Phase 1 · NCT06553339
- OxaliplatinPhase 1 · NCT05891171 · NCT06839105
- P-MUC1C-ALLO1 CAR-T cellsPhase 1 · NCT05239143
- PD-32766D (a Copper-64 [64Cu] labeled peptide)Phase 1 · NCT07688187
- PD-32766T (an Actinium-225 [225Ac] labeled peptide)Phase 1 · NCT07688187
- PDS01ADCPhase 1 · NCT04235777
- PembrollizumabPhase 1 · NCT06242470
- PemetrexedPhase 1 · NCT06839105
- Personalized Neoantigen Polyepitope Peptide VaccinePhase 1 · NCT07686744
- Phase 1a: LB-LR1109Phase 1 · NCT06332755
- Phase 1b: LB-LR1109 and AtezolizumabPhase 1 · NCT06332755
- Platinum-based ChemotherapyPhase 1 · NCT05614102
- PLN-101095Phase 1 · NCT06270706
- Positron Emission Tomography (PET)/Computerized tomography (CT)Phase 1 · NCT06942104
- Programmed Cell Death-1 (PD-1) InhibitorPhase 1 · NCT04777994
- QXL138AM Injection every 2 weeks by IV InfusionPhase 1 · NCT06582017
- RemzistotugPhase 1 · NCT05277051
- RenvastinibPhase 1 · NCT06839105
- RimiducidPhase 1 · NCT05239143
- Sapu003Phase 1 · NCT07369505
- SC-CAR.GPC3xIL15.21 CAR T cellsPhase 1 · NCT07148050
- second generation 4-1BBζ B7H3-EGFRt-DHFRPhase 1 · NCT04483778
- second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tGPhase 1 · NCT04483778
- second generation 4-1BBζ EGFR806-EGFRtPhase 1 · NCT03618381
- second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tGPhase 1 · NCT03618381
- Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cellsPhase 1 · NCT07172958
- SI-B003Phase 1 · NCT04606472
- SIM0505 for injectionPhase 1 · NCT06792552
- SitagliptinPhase 1 · NCT07634380
- Skin BiopsyPhase 1 · NCT07716735
- Standard-of-Care ImmunotherapyPhase 1 · NCT04620603
- Stereotactic Radiosurgery (SRS)Phase 1 · NCT06132945
- TaxolPhase 1 · NCT06839105
- TGFBR-2 KO CD70 CAR NKPhase 1 · NCT07072234
- Trifluridine/TipiracilPhase 1 · NCT05029882
- TTX-080Phase 1 · NCT04485013
- Tumor BiopsyPhase 1 · NCT06942104
- Tumor Treating Fields TherapyPhase 1 · NCT05092373
- UCL70805FPhase 1 · NCT07500805
- US-sourced Keytruda®Phase 1 · NCT07160335
- ValemetostatPhase 1 · NCT04388852
- Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)Phase 1 · NCT04777994
- VET3-TGIPhase 1 · NCT06444815
- vobramitamab tavatecanPhase 1 · NCT06242470
- VorinostatPhase 1 · NCT04308330
- XmAb819Phase 1 · NCT05433142
- Ziv-AfliberceptPhase 1 · NCT02298959
- ZM008Phase 1 · NCT06451497
- [64Cu]CM500Early phase 1 · NCT07781852
- [68Ga]CM500Early phase 1 · NCT07781852
- 18F-CAIXEarly phase 1 · NCT07875946
- 18F-FDGEarly phase 1 · NCT04147494
- 68Ga-CAIX PET/CTEarly phase 1 · NCT07875946
- 68Ga-XT771Early phase 1 · NCT07067905
- Blood CollectionEarly phase 1 · NCT07781852
- CAR-T(CD70)Early phase 1 · NCT07113977
- CLEAR CAR-T cell injectionEarly phase 1 · NCT07645690
- CM-BA-9Early phase 1 · NCT07865832
- Cytokine Induced Memory-like Natural Killer (CIML NK) CellsEarly phase 1 · NCT06318871
- Each patient will undergo 68Ga/18F-CAIX-LT-BCH PET/CT imaging, with an administered radioactive dose of approximately 0.05-0.1 mCi/kg.Early phase 1 · NCT07590310
- Gallium Ga 68 FAPi-46Early phase 1 · NCT04147494
- Gallium Ga 68-labeled PSMA-11Early phase 1 · NCT04147494
- Interleukin-2 (IL-2)Early phase 1 · NCT06318871
- Lenvatinib tabletEarly phase 1 · NCT05733715
- MetastasectomyEarly phase 1 · NCT02210117
- Pembrolizumab infusionEarly phase 1 · NCT05733715
- PET/CTEarly phase 1 · NCT07781852
- PET/MREarly phase 1 · NCT07781852
- Therapeutic Conventional SurgeryEarly phase 1 · NCT02210117
Closest to patients
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After SurgeryPazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After SurgeryMarshfield Medical Center · Marshfield, United States + 578 more hospitalsPhase 3Primary completion 2018
- Savolitinib vs. Sunitinib in MET-driven PRCC.Savolitinib vs. Sunitinib in MET-driven PRCC.Research Site · Omsk, Russia + 44 more hospitalsPhase 3Primary completion 2019
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaLenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaThomayerova Nemocnice · Prague, Czechia + 182 more hospitalsPhase 3Primary completion 2020
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Simvastatin enhances the antitumor activity of temsirolimus through AMPK-associated metabolic modulation in clear-cell renal cell carcinoma.
Simvastatin enhances the antitumor activity of temsirolimus through AMPK-associated metabolic modulation in clear-cell renal cell carcinoma.
Naunyn-Schmiedeberg's archives of pharmacology
PubMed · PMID 42493660Publication
Targeted co-delivery of curcumin and TRAIL via engineered extracellular vesicles: a synergistic therapy against resistant cancers.
Targeted co-delivery of curcumin and TRAIL via engineered extracellular vesicles: a synergistic therapy against resistant cancers.
Drug delivery and translational research
PubMed · PMID 42440253Publication
Shiyiwei Shenqi Pian-derived quercetin reactivates apoptosis in clear cell renal cell carcinoma by destabilizing survivin and x-linked inhibitor of apoptosis protein.
Shiyiwei Shenqi Pian-derived quercetin reactivates apoptosis in clear cell renal cell carcinoma by destabilizing survivin and x-linked inhibitor of apoptosis protein.
Phytomedicine : international journal of phytotherapy and phytopharmacology
PubMed · PMID 42435524Publication
Vitamin D Signaling from Nephrogenesis to Neoplasia: Spatial Protein Expression in Fetal Kidney and Transcriptomic Dysregulation in Renal Tumors.
Vitamin D Signaling from Nephrogenesis to Neoplasia: Spatial Protein Expression in Fetal Kidney and Transcriptomic Dysregulation in Renal Tumors.
Medicina (Kaunas, Lithuania)
PubMed · PMID 42356087
Find fellow researchers
Groups with active Kidney cancer work.
The University of Texas MD Anderson Cancer Center
Houston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
The University of Texas Southwestern Medical Center
Dallas, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Memorial Sloan Kettering Cancer Center
New York, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Brigham and Women's Hospital
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Yale University
New Haven, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Shanghai Jiao Tong University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Emory University
Atlanta, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Mayo Clinic
Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Weill Cornell Medicine
New York, United States
Team details appear once the team leader joins.
Is this your team? Claim it